Multiple Sclerosis

The monoclonal antibody — a once-weekly injection endorsed by actor Charlie Sheen — has been undergoing current clinical phases for over 2 years.

Investigators note that seasonal variation in relapse in MS has been observed, suggesting that season-dependent factors such as ambient air pollution may be involved.

Olfactory dysfunction is highly prevalent in primary progressive MS patients, especially when compared to relapsing-remitting MS patients.

Though safer for relapsing-remmitting multiple sclerosis than new disease-modifying therapies, the treatment nearly doubles the chance of a patient suffering from a stroke.

MS patients were significantly outscored by a control group in a series of social interaction tests.

Antioxidant liopic acid reported efficacy in treating secondary progressive multiple sclerosis cases.

The variant was uncovered while researchers observed a bizarre case of siblings, each with multiple sclerosis and malignant melanoma.

Allen Bowling, MD, PhD, explains the benefits and roadblocks of alternative medicine for MS.

The changes are intended to improve treatment available at affordable market prices.

A look back at what studies, headlines, and news caught our readers' eyes most throughout the month.

The TOLEDO study noted it also increased “on” time without troublesome dyskinesia.

A study looked at how anxiety and cognitive fatigue effect learning and memory in MS patients.

Data presented this weekend at the 3rd Congress of the European Academy of Neurology will show its varied efficacy in MS progression prevention.

Stephen Krieger, MD, explains how the monoclonal antibody changed the state of MS treatment.

Navigating the adverse effects, and potential benefits, for the neurological condition's treatments.

Omitted data reveals why Lemtrada's treatment of multiple sclerosis could leave patients susceptible to secondary autoimmune conditions.

The in vivo microscopy has been used in other peripheral neuropathies.

Minocycline can reduce risk of conversion over 6 months of treatment.

Simvastin proves to aid in MS patients' cognitivie burden.

An analyst explains why the RRMS drug fares well among wider competition.

John Dirk Nieland, PhD, associate professor in the Department of Health Science and Technology at Aalborg University in Denmark, discusses his research team's connection between MS and lipid metabolism, the importance of condition-inflicted models, and the encompassing nature of treating MS.

Clyde Markowitz, MD, discusses how ocrelizumab, the most recent FDA-approved multiple sclerosis (MS) treatment, doesn't need to have "blockbuster" results to progress the state of MS treatment.

"We shouldn't reject these hypotheses, we should seek more data on them.

He and a Danish team believe they've found the cause of multiple sclerosis.

Brenda Banwell, MD, FAAP, FRCPC, Children's Hospital of Philadelphia's Neurology Division chief, talks about the cruciality of early diagnosing in pediatric multiple sclerosis patients, and how their best outcome is just being able to live a normal, everyday life.

Brenda Banwell, MD, FAAP, FRCPC, chief of Childrens Hospital of Philadelphia's Division of Neurology, speaks on new discoveries of pediatric MS at the annual 2017 Consortium of Multiple Sclerosis Centers (CMSC) in New Orleans.

The multi-dosage longterm studies of Cladribine Tablets were shared at CMSC.

The study was a continuation of a 2-year alemtuzumab study versus interferon.

The director of experimental therapeutics at the Mellen MS Center at the Cleveland Clinic shared what's shaping the soon-to-be-released update on the most recent 2010 diagnosing criteria at the 2017 Consortium of Multiple Sclerosis Centers.

The Mount Sinai Hospital neurology professor shares his thoughts on MS care.